GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PPD Inc (NAS:PPD) » Definitions » PEG Ratio

PPD (PPD) PEG Ratio : N/A (As of Apr. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is PPD PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, PPD's PE Ratio without NRI is 47.52. PPD's 5-Year EBITDA growth rate is 0.00%. Therefore, PPD's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for PPD's PEG Ratio or its related term are showing as below:



PPD's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.65
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


PPD PEG Ratio Historical Data

The historical data trend for PPD's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PPD PEG Ratio Chart

PPD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
PEG Ratio
- - - - -

PPD Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PPD's PEG Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, PPD's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PPD's PEG Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PPD's PEG Ratio distribution charts can be found below:

* The bar in red indicates where PPD's PEG Ratio falls into.



PPD PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

PPD's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=47.517587939698/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


PPD  (NAS:PPD) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


PPD PEG Ratio Related Terms

Thank you for viewing the detailed overview of PPD's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PPD (PPD) Business Description

Traded in Other Exchanges
N/A
Address
929 North Front Street, Wilmington, NC, USA, 28401
PPD is a global contract research organization that provides clinical trial and laboratory services to pharmaceutical, device, and diagnostic firms. The clinical development services segment offers outsourced trial services, spanning early- and late-stage trials, as well as peri- and post-approval trials, and the laboratory services segment includes both advanced lab testing and central lab services. The company was taken private in 2011 and went public again in 2020.. Thermo Fisher Scientific announced it will acquire PPD for $17.4 billion, which is scheduled to close by the end of 2021.
Executives
H&f Corporate Investors Viii, Ltd. 10 percent owner 415 MISSION STREET, SUITE 5700, SAN FRANCISCO CA 94105
H&f Corporate Investors Vii, Ltd. 10 percent owner 415 MISSION STREET, SUITE 5700, SAN FRANCISCO CA 94105
David Michael Johnston officer: See Remarks C/O PPD, INC. 929 NORTH FRONT STREET WILMINGTON NC 28401
David S Simmons director, officer: Chief Executive Officer PFIZER INC. ATTN. CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Glen Donovan officer: Chief Accounting Officer C/O PPD, INC. 929 NORTH FRONT STREET WILMINGTON NC 28401
Ronald E Garrow officer: See Remarks 2000 PURCHASE STREET, PURCHASE NY 10577
Karen Kaucic officer: See Remarks C/O PPD, INC. 929 NORTH FRONT STREET WILMINGTON NC 28401
Judd Hartman officer: See Remarks 3124 DEVER COURT WILMINGTON NC 28411
Jill Pellegrino officer: SVP & General Manager of AES C/O PPD, INC. 929 NORTH FRONT STREET WILMINGTON NC 28401
H&f Executives Vii, L.p. 10 percent owner ONE MARITIME PLAZA 12TH FLOOR SAN FRANCISCO CA 94111
Hellman & Friedman Investors Viii, L.p. 10 percent owner 415 MISSION STREET, SUITE 5700, SAN FRANCISCO CA 94105
P. Hunter Philbrick director C/O HELLMAN & FRIEDMAN INVESTORS, ONE MARTIME PLAZA, 12TH FLOOR, SAN FRANCISCO CA 94111
Carlyle Partners Vi Holdings Ii, L.p. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004
Tc Group Vi, L.l.c. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA ANVENE, N.W., WASHINGTON DC 20004
Tc Group Vi, L.p. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004